Status:

TERMINATED

Dräger COVID-19 Antigen Test Clinical Performance Study

Lead Sponsor:

Drägerwerk AG & Co. KGaA

Conditions:

Covid19

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens. Real-time polymerase chain reaction (RT-PCR) on specimens collected by...

Detailed Description

The Dräger Antigen Test SARS-CoV-2 is a rapid lateral flow immunoassay for the qualitative detection of SARS-CoV-2 nucleoprotein directly from less invasive nasal swabs, to be performed at the point o...

Eligibility Criteria

Inclusion

  • Participants must require SARS-CoV-2 testing for the following reasons:
  • COVID-19 symptoms (Fever, cough and/or sore throat, fatigue/ general feeling of weakness, loss of sense of smell and/or taste, shortness of breath, muscle stiffness/ body aches, head cold/ running nose, etc.) on the day of testing, or
  • Known or suspected exposure to SARS-CoV-2 (contact persons etc.), or
  • Member of a group of high risk of exposure such as healthcare workers etc., or
  • Require screening for any other reason, e.g. doctor's orders, hygiene directive etc.
  • Participant must be of legal age and must be able to understand the procedure and letter of consent.

Exclusion

  • Patients younger than 18 years old are excluded from the study.
  • Pregnant or breastfeeding patients are excluded from the study.
  • Patients unable to provide written informed consent are excluded.
  • Patients with bleeding disorder are excluded from the study as a precaution.
  • Hospitalized patients/inpatients are excluded.
  • Application of nasal spray within 15 min prior to testing.
  • Participants with symptoms on the day of testing are excluded, if any of their symptoms started more than 14 days prior to testing.
  • Asymptomatic participants are excluded, if they experienced any symptoms in the 14 days prior to testing.

Key Trial Info

Start Date :

February 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 22 2021

Estimated Enrollment :

388 Patients enrolled

Trial Details

Trial ID

NCT04698993

Start Date

February 12 2021

End Date

March 22 2021

Last Update

July 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Charité - Universitätsmedizin Berlin

Berlin, Germany, 13353